Optimization of Treatment for Patients With Chronic Hepatitis C Infected With HCV-Genotype 2 or 3: 12 vs. 24 Weeks of Treatment Extension for Patients Without Rapid Virological Response.

Trial Profile

Optimization of Treatment for Patients With Chronic Hepatitis C Infected With HCV-Genotype 2 or 3: 12 vs. 24 Weeks of Treatment Extension for Patients Without Rapid Virological Response.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms OPTEX2-3
  • Most Recent Events

    • 21 Aug 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Dec 2012 Planned End Date changed from 1 Aug 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 13 Jun 2012 Planned end date changed from 1 Jul 2011 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top